Company profile: Sequana Medical
1.1 - Company Overview
Company description
- Provider of implantable pump systems to manage fluid balance by moving excess fluid to the bladder for natural elimination. Products include the Alfapump, a fully implanted device that automatically pumps fluid from the abdominal cavity into the bladder, and DSR (Direct Sodium Removal), a therapy to manage fluid overload in heart failure by controlling sodium levels.
Products and services
- DSR (Direct Sodium Removal): A sodium-focused therapy aimed at managing fluid overload in heart failure patients by controlling sodium levels to influence fluid balance
- Implantable Pump Systems: Implantable systems that manage fluid balance within the body by moving excess fluid to the bladder, where it is passed naturally through normal urination
- Alfapump System: A fully implanted device that automatically pumps fluid from the abdominal cavity into the bladder for natural elimination through normal urination, managing excess fluid
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sequana Medical
Ardelyx
HQ: United States
Website
- Description: Provider of oral therapeutics addressing mineral metabolism and metabolic disorders, including: RDX013, an investigational therapy for hyperkalemia via gut potassium secretion; RDX020, a research program targeting metabolic acidosis by inhibiting intestinal bicarbonate exchange; PHOZEVEL (tenapanor), approved in Japan for hyperphosphatemia; and IBSRELA (tenapanor), available in Canada for IBS-C.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ardelyx company profile →
Cinclus Pharma
HQ: Sweden
Website
- Description: Provider of research-based biotech solutions developing small-molecule therapies for gastric acid–related diseases, notably linaprazan glurate for GERD and Helicobacter pylori with improved action over PPIs. Completed Phase II and preparing Phase III for GERD; QIDP designation from the FDA for H. pylori. Based in Basel, Switzerland; main asset X842 studied in Phase I.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cinclus Pharma company profile →
Cosmo Pharmaceuticals
HQ: Ireland
Website
- Description: Provider of specialty pharmaceuticals and an AI-based system for real-time colorectal lesion detection, focused on gastro-intestinal diseases and optimized therapies. Manufactures generic and specialty drugs and develops innovative treatments for inflammatory bowel diseases. Portfolio includes Winlevi, GI Genius, Lialda/Mezavant/Mesavancol, Rifamycin SV MMX (Aemcolo), Byfavo, and Methylene Blue MMX.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cosmo Pharmaceuticals company profile →
Tytex
HQ: Denmark
Website
- Description: Provider of textile manufacturing services specializing in compression garments.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tytex company profile →
Torax Medical
HQ: United States
Website
- Description: Provider of treatments for digestive diseases, including acid reflux, and developer of an implantable device for gastroesophageal reflux disease; a clinical-stage medical device company founded in 2002 and based in Shoreview, Minnesota.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Torax Medical company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sequana Medical
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sequana Medical
2.2 - Growth funds investing in similar companies to Sequana Medical
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sequana Medical
4.2 - Public trading comparable groups for Sequana Medical
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →